MOLECULIN BIOTECH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.63 USD | +7.47% |
|
-0.43% | -64.04% |
| Apr. 18 | Sector Update: Health Care Stocks Ease in Afternoon Trading | MT |
| Apr. 18 | Moleculin Biotech Secures Orphan Drug Label For Annamycin in EU | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 41.85 | 50.4 | 53.15 | 30.35 | 28.68 | 10.31 | - | - |
| Enterprise Value (EV) 1 | 41.85 | 50.4 | 53.15 | 30.35 | 28.68 | 10.31 | 10.31 | 10.31 |
| P/E ratio | -2.86 x | -2.72 x | -3.15 x | -1.05 x | -0.85 x | -0.4 x | -0.57 x | -0.67 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | -0.97 x | -0.37 x | -0.31 x | -0.27 x |
| EV / FCF | -2.43 x | - | - | -1.1 x | -1.18 x | -0.36 x | -0.3 x | -0.26 x |
| FCF Yield | -41.2% | - | - | -91.3% | -84.5% | -276% | -338% | -387% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 508 | 702 | 1,905 | 1,909 | 2,228 | 2,228 | - | - |
| Reference price 2 | 82.36 | 71.74 | 27.90 | 15.90 | 12.88 | 4.630 | 4.630 | 4.630 |
| Announcement Date | 3/19/20 | 3/24/21 | 3/24/22 | 3/22/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA 1 | - | - | - | - | -29.5 | -28 | -32.9 | -38.9 |
| EBIT 1 | -17.52 | -19.74 | -22.97 | -30.64 | -29.63 | -30.67 | -33.94 | -37.2 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -13.43 | -17.36 | -15.89 | -29.02 | -29.77 | -30.2 | -33.33 | -36.53 |
| Net income 1 | -13.2 | -17.36 | -15.89 | -29.02 | -29.77 | -30.2 | -33.33 | -36.53 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -28.80 | -26.40 | -8.850 | -15.15 | -15.07 | -11.54 | -8.097 | -6.927 |
| Free Cash Flow 1 | -17.25 | - | - | -27.71 | -24.22 | -28.5 | -34.9 | -39.9 |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/24/21 | 3/24/22 | 3/22/23 | 3/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.157 | -5.206 | -7.074 | -7.434 | -9.084 | -7.048 | -8.354 | -6.411 | -5.947 | -8.919 | -7.551 | -6.828 | -7.986 | -8.204 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -4.379 | -2.826 | -6.867 | -6.777 | -8.611 | -6.77 | -7.915 | -5.976 | -5.609 | -10.27 | -7.396 | -6.698 | -7.88 | -8.124 |
| Net income 1 | -4.379 | -2.826 | -6.867 | -6.777 | -8.611 | -6.77 | -7.915 | -5.976 | -5.609 | -10.27 | -7.396 | -6.698 | -7.88 | -8.124 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -2.250 | -1.350 | -3.600 | -3.600 | -4.500 | -3.450 | -4.200 | -3.000 | -2.850 | -14.41 | -3.530 | -3.220 | -3.160 | -2.255 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/24/22 | 5/11/22 | 8/12/22 | 11/10/22 | 3/22/23 | 5/10/23 | 8/10/23 | 11/13/23 | 3/22/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -17.3 | - | - | -27.7 | -24.2 | -28.5 | -34.9 | -39.9 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.05 | - | - | 0.07 | 0.12 | - | 1 | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/19/20 | 3/24/21 | 3/24/22 | 3/22/23 | 3/22/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
4.63
USD
Average target price
35
USD
Spread / Average Target
+655.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -64.04% | 10.31M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MBRX Stock
- Financials Moleculin Biotech, Inc.
